Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.60 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20840208 | 0.93 | CRBN (0.70) | CRBNDDB1IKZF3 | |
| SCHEMBL30484097 | 0.88 | CRBN (0.70) | CRBNDDB1IKZF3 | |
| SCHEMBL21996952 | 0.88 | CRBN (0.70) | CRBNDDB1IKZF3 | |
| SCHEMBL29347241 | 0.87 | DDB1 (0.52) | CRBNDDB1IKZF3 | |
| SCHEMBL29346395 | 0.84 | CRBN (0.85) | CRBNDDB1IKZF3 | |
| SCHEMBL31748074 | 0.82 | DDB1 (0.43) | CRBNDDB1DRD2SLC6A4 | |
| SCHEMBL23945499 | 0.79 | CRBN (0.72) | CRBNDDB1IKZF3 | |
| SCHEMBL24029813 | 0.79 | CRBN (0.72) | CRBNDDB1IKZF3 | |
| SCHEMBL20845661 | 0.79 | CRBN (0.72) | CRBNDDB1IKZF3 | |
| SCHEMBL26699657 | 0.79 | CRBN (0.72) | CRBNDDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| EP-4650348-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | CRBN 1/4885DDB1 2368/4885IKZF3 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.